Literature DB >> 11512695

Dipyridamole-induced ST-segment elevation indicative of transmural myocardial ischemia--a case report.

A M Safi1, N Pillai, M Rachko, K Chaudhry, R A Stein.   

Abstract

Dipyridamole nuclear myocardial perfusion test is a safe and effective alternative to exercise nuclear perfusion testing for detecting myocardial ischemia. It is the procedure of choice in selected patients who are unable to exercise adequately. Intravenous dipyridamole causes coronary vasodilation with resultant maldistribution and heterogeneity of coronary flow in the presence of significant coronary artery disease. True ischemia, causing symptoms or ST-segment depression, is uncommon, in part because there is no increase in myocardial oxygen demand. A patient in whom myocardial ischemia developed, manifested by ST-segment elevation, during dipyridamole stress testing is described. Scintigraphic images illustrated a myocardial perfusion defect, which was consistent with coronary angiographic findings. This case report addresses the importance of dipyridamole-induced ST-segment elevation, its correlation with angiographic findings, and the need for continued hemodynamic and electrocardiographic monitoring in patients following dipyridamole infusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11512695     DOI: 10.1177/000331970105200808

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  Coronary steal and ST elevation during dipyridamole stress testing leading to coronary artery bypass grafting.

Authors:  Halil Mutlu; Jeffrey Leppo
Journal:  J Nucl Cardiol       Date:  2007-10-18       Impact factor: 5.952

2.  Coronary angiographic significance of hyperacute ST-T changes associated with regadenoson stress.

Authors:  Matthew N Peters; Onita Bhattasli; Andrew R Burchett; Lucius A Howell; Thomas A Turnage; Morgan J Katz; Patrice Delafontaine; Anand M Irimpen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.